drugset / Trial / NCT04031742
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.
Timeline
- Start
- 2019-09-29
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafolecimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Tafolecimab | Monoclonal antibody | 450 mg | Subcutaneous |